Company Overview of Ranbaxy Pharmaceuticals, Inc.
Ranbaxy Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets generic, branded, and over the counter pharmaceutical products. It offers anti-infective, cardiovascular, NSAID, anti-expectorant, analgesic, gastrointestinal, CNS, and pharmaceutical substance products for patients and medical professionals. The company’s generic products are manufactured as capsules, tablets, and suspensions. It also offers services in the areas of active pharmaceutical ingredients development and production, dosage form development and manufacturing, contract manufacturing, sales and marketing, marketing strategies, and licensing arrangements. Ranbaxy Pharmaceuticals sells its pro...
600 College Road East
Princeton, NJ 08540
Founded in 1994
Key Executives for Ranbaxy Pharmaceuticals, Inc.
Vice President of Finance
Chief Executive Officer of Ramnaxy and Managing Director of Ranbaxy
Vice President of Corporate Communications and Vice President of Government Affairs
Executive Director of Medical and Clinical Affairs
Compensation as of Fiscal Year 2013.
Ranbaxy Pharmaceuticals, Inc. Key Developments
Attorney General Eric T. Schneiderman Announces Settlement with Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc for Entering into Anticompetitive Arrangement
Feb 19 14
Attorney General Eric T. Schneiderman announced a settlement with two generic pharmaceutical manufacturers, Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., resolving concerns that an agreement between them unlawfully restricted competition. The collusive agreement, under which each of the generic drug companies committed not to challenge certain regulatory exclusivities held by the other, served to protect each party's market positions with respect to dozens of drugs, and reduced the risk that each would face greater competition for its generic drugs. The settlement requires the companies to terminate their unlawful agreement, commit not to enter into similar agreements in the future, and make a monetary payment to the State. The case also represents the latest application of recent legal precedent arising out of challenges to pay for delay agreements between brand name and generic pharmaceutical manufacturers. The agreement between Ranbaxy and Teva relates to a type of regulatory exclusivity awarded to the first manufacturer that seeks to market a generic version of a brand manufacturer's drug prior to expiration of the brand manufacturer's patents.
Ranbaxy Pharmaceuticals, Inc. Enters into an In-Licensing Agreement with Alembic Pharmaceuticals Limited
Mar 5 13
Ranbaxy Pharmaceuticals Inc. announced that it has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market Desvenlafaxine Base Extended Release Tablets in the U.S. healthcare system. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the New Drug Application (NDA) Desvenlafaxine Base Extended Release Tablets. The product is a bioequivalent version of innovator drug, Pristiq(R) by Pfizer, Inc. The market size for Pristiq(R) is USD 590 million. Desvenlafaxine Base Extended Release Tablets is indicated for the treatment of major depressive disorder. The product will be available in 50 mg and 100 mg dosage strengths. Alembic has received the final approval from the U.S. Food and Drug Administration and Ranbaxy expects the product to be available in the U.S. marketplace during the first quarter of 2013.
Gainey & McKenna Files Lawsuit Against Ranbaxy Pharmaceuticals, Inc. for Recalled Prescription Drug, Atorvastatin
Nov 29 12
Gainey & McKenna announces that a class action lawsuit has been filed in the United States District Court, District of New Jersey on behalf of a class of all purchasers of certain bottles of Atorvastatin (generic Lipitor) that were manufactured and sold by Ranbaxy Pharmaceuticals, Inc. The pharmaceutical company recently conducted a limited, voluntary recall at the retail level only for Atorvastatin calcium tablets, (generic Lipitor). The recall concerns its 10mg 20mg and 40mg dosage strengths, packaged in 90's and 500 count bottles and only with respect to certain select lot numbers. Ranbaxy admitted that the product contained glass particles. The Complaint alleges that the defendants manufactured and sold a dangerous and defective product, violated consumer fraud laws, and otherwise acted improperly with respect to the tainted Atorvastatin. The class action seeks a total product recall, with notice to consumers about the tainted product. The lawsuit also seeks a refund of the money paid for the product.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|